名稱：藥典二氧化碳（CO2）凈化裝置

型號：HHO-III Purification device

應用：2020版及2015版中國藥典二氧化碳中碳氫化合物測定  氣相色譜法

2020年版《中華人民共和國藥典》（以下簡稱《中國藥典》）已由國家藥品監督管理局 國家衛生健康委2020年第78號公告發布，自2020年12月30日起實施。現就實施本版《中國藥典》有關事宜公告如下：

一、根據《藥品管理法》的規定，藥品應當符合國家藥品標準。《中國藥典》是國家藥品標準的重要組成部分，是藥品研制、生產（進口）、經營、使用和監督管理等相關單位均應遵循的法定技術標準。

二、《中國藥典》主要由凡例、品種正文和通用技術要求構成。自實施之日起，所有生產上市藥品應當符合本版《中國藥典》相關技術要求。

三、自實施之日起，凡原收載于歷版藥典、局（部）頒標準的品種，本版《中國藥典》收載的，相應歷版藥典、局（部）頒標準同時廢止；本版《中國藥典》未收載的，仍執行相應歷版藥典、局（部）頒標準，但應符合本版《中國藥典》的相關通用技術要求，經上市后評價撤銷或注銷的品種，相應歷版藥典、局（部）頒標準廢止。

本版《中國藥典》品種正文未收載的制劑規格、中藥的制法，其質量標準按本版《中國藥典》同品種相關要求執行，規格項、制法項分別按原批準證明文件執行。

四、藥品注冊標準中收載檢驗項目多于或者異于藥典規定的，或者質量指標嚴于藥典要求的，應在執行藥典要求的基礎上，同時執行注冊標準的相應項目和指標。

藥品注冊標準收載檢驗項目少于藥典規定或質量指標低于藥典要求的，應執行藥典規定。

浩瀚色譜（山東）應用技術開發有限公司以振興民族企業為己任，根據2020中國藥典二氧化碳中規定的要求：碳氫化合物的含量不大于0.0020%的指標要求，升級改造了HHO-III Purification device凈化裝置，并命名為2021年NEW款，此款設備更加符合2020版藥典，凈化效果好，定量準確。

浩瀚色譜，提供詳細的操作方法，提供安裝圖紙。

2020年版《中華人民共和國藥典》 測試譜圖：


The 2020 edition of the Pharmacopoeia of the People's Republic of China
The 2020 edition of "The Pharmacopoeia of the People's Republic of China" Details:

Name: Pharmacopoeia carbon dioxide (CO2) purification device

Model: HHO-III Purification device

Application: 2020 and 2015 Chinese Pharmacopoeia Determination of Hydrocarbons in Carbon Dioxide Gas Chromatography


The 2020 edition of the "Pharmacopoeia of the People's Republic of China" (hereinafter referred to as the "Chinese Pharmacopoeia") has been issued by the National Medical Products Administration and National Health Commission Announcement No. 78, 2020, and will be implemented on December 30, 2020. The relevant matters concerning the implementation of this edition of the Chinese Pharmacopoeia are hereby announced as follows:

1. According to the provisions of the "Drug Administration Law", drugs should comply with national drug standards. The "Chinese Pharmacopoeia" is an important part of the national drug standards, and is a legal technical standard that should be followed by relevant units such as drug research and development, production (import), operation, use, supervision and management.

2. The "Chinese Pharmacopoeia" mainly consists of legends, variety texts and general technical requirements. From the date of implementation, all drugs produced and marketed shall meet the relevant technical requirements of this edition of the Chinese Pharmacopoeia.

3. From the date of implementation, all varieties that were originally included in the pharmacopoeias of the calendar and the standards issued by the bureaus (ministries), and those included in this edition of the Chinese Pharmacopoeia, the corresponding pharmacopoeias and the standards issued by the bureaus (ministers) shall be abolished simultaneously; If this edition of the "Chinese Pharmacopoeia" is not included, the corresponding historical editions of the pharmacopoeia and bureau (ministerial) standards shall still be implemented, but should comply with the relevant general technical requirements of this edition of the "Chinese Pharmacopoeia". Corresponding historical editions of the pharmacopoeia, bureau (minister) issued standards are abolished.

The quality standards of preparation specifications and preparation methods of traditional Chinese medicines that are not included in the text of this edition of the Chinese Pharmacopoeia shall be implemented in accordance with the relevant requirements of the same variety in this edition of the Chinese Pharmacopoeia, and specifications and preparation items shall be implemented in accordance with the original approval documents.

4. If the drug registration standard contains more inspection items than or different from the pharmacopoeia, or the quality index is stricter than the pharmacopoeia requirements, the corresponding items and indicators of the registration standard shall be implemented on the basis of the pharmacopoeia requirements.

If the inspection items included in the drug registration standards are less than the pharmacopoeia regulations or the quality index is lower than the pharmacopoeia requirements, the pharmacopoeia regulations shall be implemented.





Haohan Chromatography (Shandong) Applied Technology Development Co., Ltd. takes the revitalization of national enterprises as its mission. According to the requirements stipulated in the 2020 Chinese Pharmacopoeia for carbon dioxide: the content of hydrocarbons is not more than 0.0020%, the HHO-III Purification device has been upgraded and transformed. , And named the 2021 NEW model, this device is more in line with the 2020 version of the Pharmacopoeia, with good purification effect, accurate and reliable quantification.

Haohan Chromatography provides detailed operation methods and installation drawings.


The test spectrum of the 2020 edition of "The Pharmacopoeia of People's Republic of China"